Disease trajectories in interstitial lung diseases - data from the EXCITING-ILD registry.
ILD
IPF
Mortality
Progression
Risk factors
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
06 Mar 2024
06 Mar 2024
Historique:
received:
02
01
2024
accepted:
13
02
2024
medline:
7
3
2024
pubmed:
7
3
2024
entrez:
6
3
2024
Statut:
epublish
Résumé
Interstitial lung diseases (ILD) comprise a heterogeneous group of mainly chronic lung diseases with different disease trajectories. Progression (PF-ILD) occurs in up to 50% of patients and is associated with increased mortality. The EXCITING-ILD (Exploring Clinical and Epidemiological Characteristics of Interstitial Lung Diseases) registry was analysed for disease trajectories in different ILD. The course of disease was classified as significant (absolute forced vital capacity FVC decline > 10%) or moderate progression (FVC decline 5-10%), stable disease (FVC decline or increase < 5%) or improvement (FVC increase ≥ 5%) during time in registry. A second definition for PF-ILD included absolute decline in FVC % predicted ≥ 10% within 24 months or ≥ 1 respiratory-related hospitalisation. Risk factors for progression were determined by Cox proportional-hazard models and by logistic regression with forward selection. Kaplan-Meier curves were utilised to estimate survival time and time to progression. Within the EXCITING-ILD registry 28.5% of the patients died (n = 171), mainly due to ILD (n = 71, 41.5%). Median survival time from date of diagnosis on was 15.5 years (range 0.1 to 34.4 years). From 601 included patients, progression was detected in 50.6% of the patients (n = 304) with shortest median time to progression in idiopathic NSIP (iNSIP; median 14.6 months) and idiopathic pulmonary fibrosis (IPF; median 18.9 months). Reasons for the determination as PF-ILD were mainly deterioration in lung function (PFT; 57.8%) and respiratory hospitalisations (40.6%). In multivariate analyses reduced baseline FVC together with age were significant predictors for progression (OR = 1.00, p < 0.001). Higher GAP indices were a significant risk factor for a shorter survival time (GAP stage III vs. I HR = 9.06, p < 0.001). A significant shorter survival time was found in IPF compared to sarcoidosis (HR = 0.04, p < 0.001), CTD-ILD (HR = 0.33, p < 0.001), and HP (HR = 0.30, p < 0.001). Patients with at least one reported ILD exacerbation as a reason for hospitalisation had a median survival time of 7.3 years (range 0.1 to 34.4 years) compared to 19.6 years (range 0.3 to 19.6 years) in patients without exacerbations (HR = 0.39, p < 0.001). Disease progression is common in all ILD and associated with increased mortality. Most important risk factors for progression are impaired baseline forced vital capacity and higher age, as well as acute exacerbations and respiratory hospitalisations for mortality. Early detection of progression remains challenging, further clinical criteria in addition to PFT might be helpful.
Sections du résumé
BACKGROUND
BACKGROUND
Interstitial lung diseases (ILD) comprise a heterogeneous group of mainly chronic lung diseases with different disease trajectories. Progression (PF-ILD) occurs in up to 50% of patients and is associated with increased mortality.
METHODS
METHODS
The EXCITING-ILD (Exploring Clinical and Epidemiological Characteristics of Interstitial Lung Diseases) registry was analysed for disease trajectories in different ILD. The course of disease was classified as significant (absolute forced vital capacity FVC decline > 10%) or moderate progression (FVC decline 5-10%), stable disease (FVC decline or increase < 5%) or improvement (FVC increase ≥ 5%) during time in registry. A second definition for PF-ILD included absolute decline in FVC % predicted ≥ 10% within 24 months or ≥ 1 respiratory-related hospitalisation. Risk factors for progression were determined by Cox proportional-hazard models and by logistic regression with forward selection. Kaplan-Meier curves were utilised to estimate survival time and time to progression.
RESULTS
RESULTS
Within the EXCITING-ILD registry 28.5% of the patients died (n = 171), mainly due to ILD (n = 71, 41.5%). Median survival time from date of diagnosis on was 15.5 years (range 0.1 to 34.4 years). From 601 included patients, progression was detected in 50.6% of the patients (n = 304) with shortest median time to progression in idiopathic NSIP (iNSIP; median 14.6 months) and idiopathic pulmonary fibrosis (IPF; median 18.9 months). Reasons for the determination as PF-ILD were mainly deterioration in lung function (PFT; 57.8%) and respiratory hospitalisations (40.6%). In multivariate analyses reduced baseline FVC together with age were significant predictors for progression (OR = 1.00, p < 0.001). Higher GAP indices were a significant risk factor for a shorter survival time (GAP stage III vs. I HR = 9.06, p < 0.001). A significant shorter survival time was found in IPF compared to sarcoidosis (HR = 0.04, p < 0.001), CTD-ILD (HR = 0.33, p < 0.001), and HP (HR = 0.30, p < 0.001). Patients with at least one reported ILD exacerbation as a reason for hospitalisation had a median survival time of 7.3 years (range 0.1 to 34.4 years) compared to 19.6 years (range 0.3 to 19.6 years) in patients without exacerbations (HR = 0.39, p < 0.001).
CONCLUSION
CONCLUSIONS
Disease progression is common in all ILD and associated with increased mortality. Most important risk factors for progression are impaired baseline forced vital capacity and higher age, as well as acute exacerbations and respiratory hospitalisations for mortality. Early detection of progression remains challenging, further clinical criteria in addition to PFT might be helpful.
Identifiants
pubmed: 38448953
doi: 10.1186/s12931-024-02731-3
pii: 10.1186/s12931-024-02731-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
113Informations de copyright
© 2024. The Author(s).
Références
Valeyre D, Duchemann B, Annesi-Maesano I et al. Interstitial lung diseases, in Respiratory Epidemiology, T. Welte, I. Annesi-Maesano, G. Viegi, and B. Lundbäck,Eds., vol. 65 of ERSMonograph, Chap. 6, ERS, 2014.
American Thoracic Society and European Respiratory Society. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2002;165(2):277–304.
doi: 10.1164/ajrccm.165.2.ats01
Travis WD, Costabel U, Hansell D. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188(6):733–48.
doi: 10.1164/rccm.201308-1483ST
pubmed: 24032382
pmcid: 5803655
Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, Kreuter M, Lynch DA, Maher TM, Martinez FJ, Molina-Molina M, Myers JL, Nicholson AG, Ryerson CJ, Strek ME, Troy LK, Wijsenbeek M, Mammen MJ, Hossain T, Bissell BD, Herman DD, Hon SM, Kheir F, Khor YH, Macrea M, Antoniou KM, Bouros D, Buendia-Roldan I, Caro F, Crestani B, Ho L, Morisset J, Olson AL, Podolanczuk A, Poletti V, Selman M, Ewing T, Jones S, Knight SL, Ghazipura M, Wilson KC. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022;205(9):e18–e47.
doi: 10.1164/rccm.202202-0399ST
pubmed: 35486072
pmcid: 9851481
Valenzuela C, Cottin V. Epidemiology and real-life experience in progressive pulmonary fibrosis. Curr Opin Pulm Med. 2022;28(5):407–13. https://doi.org/10.1097/MCP.0000000000000908 .
doi: 10.1097/MCP.0000000000000908
pubmed: 35938201
Cottin V, Hirani NA, Hotchkin DL, Nambiar AM, Ogura T, Otaola M, Skowasch D, Park JS, Poonyagariyagorn HK, Wuyts W, Wells AU. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018;27(150):180076. https://doi.org/10.1183/16000617.0076-2018 .
doi: 10.1183/16000617.0076-2018
pubmed: 30578335
pmcid: 9489068
Wijsenbeek M, Cottin V. Spectrum of Fibrotic Lung diseases. N Engl J Med. 2020;383(10):958–68. https://doi.org/10.1056/NEJMra2005230 .
doi: 10.1056/NEJMra2005230
pubmed: 32877584
Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, Richeldi L, Kolb M, Tetzlaff K, Stowasser S, Coeck C, Clerisme-Beaty E, Rosenstock B, Quaresma M, Haeufel T, Goeldner RG, Schlenker-Herceg R, Brown KK. INBUILD Trial investigators. Nintedanib in Progressive Fibrosing interstitial lung diseases. N Engl J Med. 2019;381(18):1718–27. https://doi.org/10.1056/NEJMoa1908681 .
doi: 10.1056/NEJMoa1908681
pubmed: 31566307
Behr J, Prasse A, Kreuter M, Johow J, Rabe KF, Bonella F, Bonnet R, Grohe C, Held M, Wilkens H, Hammerl P, Koschel D, Blaas S, Wirtz H, Ficker JH, Neumeister W, Schönfeld N, Claussen M, Kneidinger N, Frankenberger M, Hummler S, Kahn N, Tello S, Freise J, Welte T, Neuser P, Günther A. RELIEF investigators. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med. 2021;9(5):476–86. https://doi.org/10.1016/S2213-2600(20)30554-3 .
doi: 10.1016/S2213-2600(20)30554-3
pubmed: 33798455
Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, Axmann J, Kirchgaessler KU, Samara K, Gilberg F, Cottin V. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2020;8(2):147–57. https://doi.org/10.1016/S2213-2600(19)30341-8 .
doi: 10.1016/S2213-2600(19)30341-8
pubmed: 31578169
Hambly N, Farooqi MM, Dvorkin-Gheva A, Donohoe K, Garlick K, Scallan C, Chong SG, MacIsaac S, Assayag D, Johannson KA, Fell CD, Marcoux V, Manganas H, Morisset J, Comes A, Fisher JH, Shapera S, Gershon AS, To T, Wong AW, Sadatsafavi M, Wilcox PG, Halayko AJ, Khalil N, Cox G, Richeldi L, Ryerson CJ, Kolb M. Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry. Eur Respir J. 2022;60(4):2102571. https://doi.org/10.1183/13993003.02571-2021 .
doi: 10.1183/13993003.02571-2021
pubmed: 35273032
Nasser M, Larrieu S, Si-Mohamed S, Ahmad K, Boussel L, Brevet M, Chalabreysse L, Fabre C, Marque S, Revel D, Thivolet-Bejui F, Traclet J, Zeghmar S, Maucort-Boulch D, Cottin V. Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study). Eur Respir J. 2021;57(2):2002718. https://doi.org/10.1183/13993003.02718-2020 .
doi: 10.1183/13993003.02718-2020
pubmed: 32943410
pmcid: 8411897
Wijsenbeek M, Kreuter M, Olson A, Fischer A, Bendstrup E, Wells CD, Denton CP, Mounir B, Zouad-Lejour L, Quaresma M, Cottin V. Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management. Curr Med Res Opin. 2019;35(11):2015–24. https://doi.org/10.1080/03007995.2019.1647040 .
doi: 10.1080/03007995.2019.1647040
pubmed: 31328965
Kreuter M, Herth FJ, Wacker M, Leidl R, Hellmann A, Pfeifer M, Behr J, Witt S, Kauschka D, Mall M, Günther A, Markart P. Exploring clinical and epidemiological characteristics of interstitial Lung diseases: Rationale, Aims, and design of a nationwide prospective Registry–The EXCITING-ILD Registry. Biomed Res Int. 2015;2015:123876. https://doi.org/10.1155/2015/123876 .
doi: 10.1155/2015/123876
pubmed: 26640781
pmcid: 4657073
Buschulte K, Kabitz HJ, Hagmeyer L, Hammerl P, Esselmann A, Wiederhold C, Skowasch D, Stolpe C, Joest M, Veitshans S, Höffgen M, Maqhuzu P, Schwarzkopf L, Hellmann A, Pfeifer M, Behr J, Karpavicius R, Günther A, Polke M, Höger P, Somogyi V, Lederer C, Markart P, Kreuter M. Hospitalisation patterns in interstitial lung diseases: data from the EXCITING-ILD registry. Respir Res. 2024 Jan 4;25(1):5. https://doi.org/10.1186/s12931-023-02588-y . PMID: 38178212; PMCID: PMC10765927.
Hoffmann-Vold AM, Allanore Y, Alves M, Brunborg C, Airó P, Ananieva LP, Czirják L, Guiducci S, Hachulla E, Li M, Mihai C, Riemekasten G, Sfikakis PP, Kowal-Bielecka O, Riccardi A, Distler O. EUSTAR collaborators. Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. Ann Rheum Dis. 2021;80(2):219–27. https://doi.org/10.1136/annrheumdis-2020-217455 .
doi: 10.1136/annrheumdis-2020-217455
pubmed: 32988845
Ryerson CJ, Vittinghoff E, Ley B, Lee JS, Mooney JJ, Jones KD, Elicker BM, Wolters PJ, Koth LL, King TE Jr, Collard HR. Predicting survival across chronic interstitial lung disease: the ILD-GAP model. Chest. 2014;145(4):723–8. https://doi.org/10.1378/chest.13-1474 .
doi: 10.1378/chest.13-1474
pubmed: 24114524
Cottin V, Schmidt A, Catella L, Porte F, Fernandez-Montoya C, Le Lay K, Bénard S. Burden of idiopathic pulmonary fibrosis progression: a 5-Year longitudinal Follow-Up study. PLoS ONE. 2017;12(1):e0166462. https://doi.org/10.1371/journal.pone.0166462 .
doi: 10.1371/journal.pone.0166462
pubmed: 28099456
pmcid: 5242514
Brown AW, Fischer CP, Shlobin OA, Buhr RG, Ahmad S, Weir NA, Nathan SD. Outcomes after hospitalization in idiopathic pulmonary fibrosis: a cohort study. Chest. 2015;147(1):173–9.
doi: 10.1378/chest.13-2424
pubmed: 25188694
Wälscher J, Witt S, Schwarzkopf L, Kreuter M. Hospitalisation patterns of patients with interstitial lung disease in the light of comorbidities and medical treatment - a German claims data analysis. Respir Res. 2020;21(1):73.
doi: 10.1186/s12931-020-01335-x
pubmed: 32216792
pmcid: 7098099
Torrisi SE, Kahn N, Wälscher J, Polke M, Lee JS, Molyneaux PL, Sambataro FM, Heussel CP, Vancheri C, Kreuter M. Outcomes and incidence of PF-ILD according to different definitions in a Real-World setting. Front Pharmacol. 2021;12:790204. https://doi.org/10.3389/fphar.2021.790204 .
doi: 10.3389/fphar.2021.790204
pubmed: 34975486
pmcid: 8718675
Ma X, Zhu L, Kurche JS, Xiao H, Dai H, Wang C. Global and regional burden of interstitial lung disease and pulmonary sarcoidosis from 1990 to 2019: results from the Global Burden of Disease study 2019. Thorax. 2022;77(6):596–605. https://doi.org/10.1136/thoraxjnl-2020-216732 .
doi: 10.1136/thoraxjnl-2020-216732
pubmed: 34556551
Kreuter M, Koegler H, Trampisch M, Geier S, Richeldi L. Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS® trials. Respir Res. 2019;20(1):71. https://doi.org/10.1186/s12931-019-1037-7 .
doi: 10.1186/s12931-019-1037-7
pubmed: 30971229
pmcid: 6458653
Hariri LP, Mino-Kenudson M, Shea B, Digumarthy S, Onozato M, Yagi Y, Fraire AE, Matsubara O, Mark EJ. Distinct histopathology of acute onset or abrupt exacerbation of hypersensitivity pneumonitis. Hum Pathol. 2012;43(5):660–8. https://doi.org/10.1016/j.humpath.2011.06.001 .
doi: 10.1016/j.humpath.2011.06.001
pubmed: 21855112
Kreuter M, Bendstrup E, Kondoh Y, et al. On behalf of the INBUILD trial investigators Acute exacerbations in patients with Progressive Fibrosing interstitial lung diseases: data from the INBUILD Trial.B94. LEARNING FROM REGISTRIES AND CLINICAL TRIALS IN ILD. American Thoracic Society; 2022. pp. A3428–8.
Kreuter M, Behr J, Bonella F, Costabel U, Gerber A, Hamer OW, Heussel CP, Jonigk D, Krause A, Koschel D, Leuschner G, Markart P, Nowak D, Pfeifer M, Prasse A, Wälscher J, Winter H, Kabitz HJ. S1-Leitlinie Interdisziplinäre Diagnostik Interstitieller Lungenerkrankungen Im Erwachsenenalter [Consensus guideline on the interdisciplinary diagnosis of interstitial lung diseases]. Pneumologie. 2023;77(5):269–302. https://doi.org/10.1055/a-2017-8971 . German.
doi: 10.1055/a-2017-8971
pubmed: 36977470
Torrisi SE, Ley B, Kreuter M, Wijsenbeek M, Vittinghoff E, Collard HR, Vancheri C. The added value of comorbidities in predicting survival in idiopathic pulmonary fibrosis: a multiCenter observational study. Eur Respir J. 2019;53(3):1801587. https://doi.org/10.1183/13993003.01587-2018 .
doi: 10.1183/13993003.01587-2018
pubmed: 30578385